Algoritmo diagnostico-terapeutico nei tumori neuroendocrini

Translated title of the contribution: Diagnostic-therapeutic algorithm of neuroendocrine tumors

A. Faggiano, F. Milone, V. Ramundo, G. Lombardi, A. Colao

Research output: Contribution to journalArticle

Abstract

Neuroendocrine tumors are a heterogeneous group of neoplasms that have in common the expression of specific molecules, proteins and receptors that constitute the neuroendocrine phenotype. This biological peculiarity is extremely useful for the diagnosis and the follow up and different molecular pathways can be used as focused therapeutic targets. Although these tumors are characterized by a high neuroendocrine secretory activity, only a minority of them arises with a specific hyper-secretory endocrine syndrome. Usually, the diagnosis is made fortuitously during a radiological exam or during a surgical operation. For this reason, histological and immunohistochemical characterization is extremely important and it must follow the international criteria of the last WHO classification of neuroendocrine tumors. Once the diagnosis of neuroendocrine tumor has been confirmed it is necessary to make an accurate evaluation of biological markers, that are useful for the identification of the primary tumor and for the follow up. Radiological evaluation includes conventional radiological techniques such as ultrasonography, computed tomography and magnetic resonance imaging, endoscopic and echo-endoscopic procedures and nuclear-medicine techniques like octreoscan. All of these should be performed in a multidisciplinary context and in specialized centres. The same should be done for therapeutic procedures, that should consider all of the therapeutic possibilities that are today available for neuroendocrine tumors including conventional anti-cancer therapies such as surgery and non conventional therapies, such as biotherapy (somatostatin analogues and Interferon), radio-receptorial therapies and locoregional therapies. Chemotherapy should be restricted to the most aggressive tumors. Nowadays new compounds are available or under evaluation in clinical trials. The therapeutic strategy should be modulated considering clinical and biological aggressiveness of the tumor and should be based not only on tumor responsiveness to treatment, but alsoon survival and the quality of life of the patients.

Original languageItalian
Pages (from-to)23-27
Number of pages5
JournalRivista Medica
Volume13
Issue number2
Publication statusPublished - Jun 2007

Fingerprint

Neuroendocrine Tumors
Neoplasms
Therapeutics
Biological Therapy
Nuclear Medicine
Somatostatin
Radio
Interferons
Ultrasonography
Biomarkers
Tomography
Quality of Life
Magnetic Resonance Imaging
Clinical Trials
Phenotype
Drug Therapy
Survival

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Faggiano, A., Milone, F., Ramundo, V., Lombardi, G., & Colao, A. (2007). Algoritmo diagnostico-terapeutico nei tumori neuroendocrini. Rivista Medica, 13(2), 23-27.

Algoritmo diagnostico-terapeutico nei tumori neuroendocrini. / Faggiano, A.; Milone, F.; Ramundo, V.; Lombardi, G.; Colao, A.

In: Rivista Medica, Vol. 13, No. 2, 06.2007, p. 23-27.

Research output: Contribution to journalArticle

Faggiano, A, Milone, F, Ramundo, V, Lombardi, G & Colao, A 2007, 'Algoritmo diagnostico-terapeutico nei tumori neuroendocrini', Rivista Medica, vol. 13, no. 2, pp. 23-27.
Faggiano A, Milone F, Ramundo V, Lombardi G, Colao A. Algoritmo diagnostico-terapeutico nei tumori neuroendocrini. Rivista Medica. 2007 Jun;13(2):23-27.
Faggiano, A. ; Milone, F. ; Ramundo, V. ; Lombardi, G. ; Colao, A. / Algoritmo diagnostico-terapeutico nei tumori neuroendocrini. In: Rivista Medica. 2007 ; Vol. 13, No. 2. pp. 23-27.
@article{c560968e9a8946c5a8a4d59f4c62910e,
title = "Algoritmo diagnostico-terapeutico nei tumori neuroendocrini",
abstract = "Neuroendocrine tumors are a heterogeneous group of neoplasms that have in common the expression of specific molecules, proteins and receptors that constitute the neuroendocrine phenotype. This biological peculiarity is extremely useful for the diagnosis and the follow up and different molecular pathways can be used as focused therapeutic targets. Although these tumors are characterized by a high neuroendocrine secretory activity, only a minority of them arises with a specific hyper-secretory endocrine syndrome. Usually, the diagnosis is made fortuitously during a radiological exam or during a surgical operation. For this reason, histological and immunohistochemical characterization is extremely important and it must follow the international criteria of the last WHO classification of neuroendocrine tumors. Once the diagnosis of neuroendocrine tumor has been confirmed it is necessary to make an accurate evaluation of biological markers, that are useful for the identification of the primary tumor and for the follow up. Radiological evaluation includes conventional radiological techniques such as ultrasonography, computed tomography and magnetic resonance imaging, endoscopic and echo-endoscopic procedures and nuclear-medicine techniques like octreoscan. All of these should be performed in a multidisciplinary context and in specialized centres. The same should be done for therapeutic procedures, that should consider all of the therapeutic possibilities that are today available for neuroendocrine tumors including conventional anti-cancer therapies such as surgery and non conventional therapies, such as biotherapy (somatostatin analogues and Interferon), radio-receptorial therapies and locoregional therapies. Chemotherapy should be restricted to the most aggressive tumors. Nowadays new compounds are available or under evaluation in clinical trials. The therapeutic strategy should be modulated considering clinical and biological aggressiveness of the tumor and should be based not only on tumor responsiveness to treatment, but alsoon survival and the quality of life of the patients.",
keywords = "Diagnostic algorithm, Neuroendocrine tumor, Therapeutic algorithm",
author = "A. Faggiano and F. Milone and V. Ramundo and G. Lombardi and A. Colao",
year = "2007",
month = "6",
language = "Italian",
volume = "13",
pages = "23--27",
journal = "Rivista Medica",
issn = "1127-6339",
publisher = "New Magazine Edizioni S.r.l.",
number = "2",

}

TY - JOUR

T1 - Algoritmo diagnostico-terapeutico nei tumori neuroendocrini

AU - Faggiano, A.

AU - Milone, F.

AU - Ramundo, V.

AU - Lombardi, G.

AU - Colao, A.

PY - 2007/6

Y1 - 2007/6

N2 - Neuroendocrine tumors are a heterogeneous group of neoplasms that have in common the expression of specific molecules, proteins and receptors that constitute the neuroendocrine phenotype. This biological peculiarity is extremely useful for the diagnosis and the follow up and different molecular pathways can be used as focused therapeutic targets. Although these tumors are characterized by a high neuroendocrine secretory activity, only a minority of them arises with a specific hyper-secretory endocrine syndrome. Usually, the diagnosis is made fortuitously during a radiological exam or during a surgical operation. For this reason, histological and immunohistochemical characterization is extremely important and it must follow the international criteria of the last WHO classification of neuroendocrine tumors. Once the diagnosis of neuroendocrine tumor has been confirmed it is necessary to make an accurate evaluation of biological markers, that are useful for the identification of the primary tumor and for the follow up. Radiological evaluation includes conventional radiological techniques such as ultrasonography, computed tomography and magnetic resonance imaging, endoscopic and echo-endoscopic procedures and nuclear-medicine techniques like octreoscan. All of these should be performed in a multidisciplinary context and in specialized centres. The same should be done for therapeutic procedures, that should consider all of the therapeutic possibilities that are today available for neuroendocrine tumors including conventional anti-cancer therapies such as surgery and non conventional therapies, such as biotherapy (somatostatin analogues and Interferon), radio-receptorial therapies and locoregional therapies. Chemotherapy should be restricted to the most aggressive tumors. Nowadays new compounds are available or under evaluation in clinical trials. The therapeutic strategy should be modulated considering clinical and biological aggressiveness of the tumor and should be based not only on tumor responsiveness to treatment, but alsoon survival and the quality of life of the patients.

AB - Neuroendocrine tumors are a heterogeneous group of neoplasms that have in common the expression of specific molecules, proteins and receptors that constitute the neuroendocrine phenotype. This biological peculiarity is extremely useful for the diagnosis and the follow up and different molecular pathways can be used as focused therapeutic targets. Although these tumors are characterized by a high neuroendocrine secretory activity, only a minority of them arises with a specific hyper-secretory endocrine syndrome. Usually, the diagnosis is made fortuitously during a radiological exam or during a surgical operation. For this reason, histological and immunohistochemical characterization is extremely important and it must follow the international criteria of the last WHO classification of neuroendocrine tumors. Once the diagnosis of neuroendocrine tumor has been confirmed it is necessary to make an accurate evaluation of biological markers, that are useful for the identification of the primary tumor and for the follow up. Radiological evaluation includes conventional radiological techniques such as ultrasonography, computed tomography and magnetic resonance imaging, endoscopic and echo-endoscopic procedures and nuclear-medicine techniques like octreoscan. All of these should be performed in a multidisciplinary context and in specialized centres. The same should be done for therapeutic procedures, that should consider all of the therapeutic possibilities that are today available for neuroendocrine tumors including conventional anti-cancer therapies such as surgery and non conventional therapies, such as biotherapy (somatostatin analogues and Interferon), radio-receptorial therapies and locoregional therapies. Chemotherapy should be restricted to the most aggressive tumors. Nowadays new compounds are available or under evaluation in clinical trials. The therapeutic strategy should be modulated considering clinical and biological aggressiveness of the tumor and should be based not only on tumor responsiveness to treatment, but alsoon survival and the quality of life of the patients.

KW - Diagnostic algorithm

KW - Neuroendocrine tumor

KW - Therapeutic algorithm

UR - http://www.scopus.com/inward/record.url?scp=34248209569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248209569&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:34248209569

VL - 13

SP - 23

EP - 27

JO - Rivista Medica

JF - Rivista Medica

SN - 1127-6339

IS - 2

ER -